Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share.
October 21, 2020
· 4 min read